Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

ABIONYX Pharma SA (609) AI Stock Analysis

DE:609

ABIONYX Pharma SA

(Frankfurt:609)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Therapeutic Platform FocusThe company has a defined biological platform centered on apoA-I and HDL-mimetic approaches, which can support multiple therapeutic applications. Concentrating research around a coherent mechanism may improve development efficiency and create opportunities to extend the platform across serious unmet medical needs.
Negative Factors
Persistent Operating LossesOperating losses remain extremely large relative to revenue, showing that the current business base does not yet cover the company’s cost structure. Until revenue scales materially or expenses decline, profitability will remain dependent on external funding and clinical or commercial progress.

ABIONYX Pharma SA (609) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%DE:609-58.97%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 70.84M
Dividend Yield
―
Average Volume (3M)
6,633
Price to Earnings (P/E)
-7.3
Beta (1Y)
-0.32
Revenue Growth
-10.38%
EPS Growth
-72.05%
Country
Germany
Employees
49
Sector
General
Sector Strength
55
Industry
Biotechnology

ABIONYX Pharma SA Business Overview & Revenue Model

Company Description

ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This...

ABIONYX Pharma SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

DE:609 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
FR:SIGHTFR:SIGHT46NeutralEUR 18.98M-1.0652.39%―-610.31%43.88%
FR:ALSENFR:ALSEN45NeutralEUR 87.32M-2.04-54.15%――6.26%

* General Sector Average

Performance Comparison

-50%0%50%100%DE:609FR:ALCOXFR:SIGHTFR:ALSENDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:609 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:609ABIONYX Pharma SA1.62-2.46-60.31%
FR:ALCOXNicox SA0.30-0.04-12.06%
FR:SIGHTGenSight Biologics0.08-0.05-38.89%
FR:ALSENSensorion SAS8.64-8.86-50.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.